Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis

J. McVernon*, Nicholas Andrews, M. P.E. Slack, Mary Ramsay

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

162 Citations (Scopus)

Abstract

An increase in invasive Hib disease incidence in the UK has coincided with the distribution of combination vaccines that contain acellular pertussis (DTaP-Hib). These vaccines have been associated with reduced immunogenicity of the Hib component, although there is little agreement on the clinical relevance of this finding. We retrospectively compared vaccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age-matched controls using conditional logistic regression. More cases than controls received all three doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14.07]).

Original languageEnglish
Pages (from-to)1521-1523
Number of pages3
JournalThe Lancet
Volume361
Issue number9368
DOIs
Publication statusPublished - 3 May 2003

Fingerprint

Dive into the research topics of 'Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis'. Together they form a unique fingerprint.

Cite this